Global Commercial Insights From The Biologics Market
Inside the report, you’ll find the latest data-driven insights shaping the future of biologics across investment, dealmaking, and innovation.
- $2 Trillion+ in Investments
Uncover how biologics overtook small molecules in total deal value and where capital is heading next. - Real-Time Deal Trends
Explore 376 biologics deals already announced in 2025, with detailed insight into structure, value, and modality focus. - Next-Gen Modalities Gaining Momentum
Dive into the rise of bispecifics, ADCs, and radioimmunoconjugates—and what this means for licensing and collaboration. - M&A is Evolving
Discover why acquirers are shifting from large, late-stage companies to innovative early-stage biotechs with differentiated platforms. - Geographic Growth & Global Players
See how Asia’s biologics ecosystem is expanding and which regions are driving deal activity.
Get the Insights That Matter
Download the report today to gain exclusive access to commercial data and strategic intelligence on the biologics landscape in 2025.
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
